Sensei Biotherapeutics Inc (SNSE)
0.475
-0.11
(-18.89%)
USD |
NASDAQ |
Oct 31, 16:00
0.50
+0.02
(+5.26%)
After-Hours: 20:00
Sensei Biotherapeutics Cash from Operations (TTM): -24.23M for June 30, 2024
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
Date | Value |
---|---|
June 30, 2024 | -24.23M |
March 31, 2024 | -27.90M |
December 31, 2023 | -32.02M |
September 30, 2023 | -35.43M |
June 30, 2023 | -37.58M |
March 31, 2023 | -40.01M |
December 31, 2022 | -39.03M |
September 30, 2022 | -37.32M |
Date | Value |
---|---|
June 30, 2022 | -36.09M |
March 31, 2022 | -30.24M |
December 31, 2021 | -30.26M |
September 30, 2021 | -25.07M |
June 30, 2021 | -25.29M |
March 31, 2021 | -22.01M |
December 31, 2020 | -17.70M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-40.01M
Minimum
Mar 2023
-17.70M
Maximum
Dec 2020
-30.68M
Average
-30.26M
Median
Dec 2021
Cash from Operations (TTM) Benchmarks
Relmada Therapeutics Inc | -48.18M |
Genprex Inc | -20.79M |
Ensysce Biosciences Inc | -9.783M |
IN8bio Inc | -24.57M |
NovaBay Pharmaceuticals Inc | -3.388M |